ACLY Cancer Research Results

ACLY, ATP citrate lyase: Click to Expand ⟱
Source:
Type:
ACLY links energy metabolism provided by catabolic pathways to biosynthesis. ACLY, which has been found to be overexpressed in many cancers, converts citrate into acetyl-CoA and OAA.ATP citrate lyase exhibited upregulation in various tumours.
General Tumour Biomarker
ACLY is a key enzyme in cancer metabolism.
ACLY is involved in glucose and lipid metabolism.
•Many ACLY inhibitors were developed as anti-cancer agents.

ACLY is a key enzyme in cellular metabolism that converts citrate into acetyl‐CoA and oxaloacetate. Acetyl‐CoA is a substrate for lipid synthesis and protein acetylation, processes that are often upregulated in cancer cells to support rapid growth and proliferation.

ACLY is found overexpressed in many aggressive cancers. ACLY abundantly consumes citrate from nutrient catabolism (especially glucose and glutamine) to support protein acetylation and intense nucleotide and lipid synthesis. The significant decrease in cytosolic citrate appears to play a central role in cancer metabolism by enhancing the Warburg effect and activating the PI3K / AKT axis promoting ACLY activity in a feedback loop. Thus, the inhibition of factors regulating its expression (such as SREBP1) and its activation (such as AKT) could have an anti-proliferative effect.

Elevated ACLY expression has been observed in a number of cancers. In many studies, high levels of ACLY have been associated with more aggressive disease and poorer prognoses.

Natural ACLY Inhibitors
-Hydroxycitrate (HCA):(widely studied)
-EGCG
-Quercetin
-Resveratrol
-Luteolin
-Citrate
-Cucurbitacin B
-Emodin?


Nor, Normal Healthy: Click to Expand ⟱
Normal Healthy

Scientific Papers found: Click to Expand⟱
5509- bemA,    Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
- Review, Nor, NA
LDL↓, AMPK↑, ACLY↓,
5514- bemA,    Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
- Trial, Nor, NA
*ACLY↓, *LDL↓, *MusCon↓, Dose↝, cardioP↑,
1625- HCA,    In S. cerevisiae hydroxycitric acid antagonizes chronological aging and apoptosis regardless of citrate lyase
- Review, Nor, NA
CRM↑, ACLY↓, TumAuto↑, Inflam↓, TumCG↓, toxicity∅, lipoGen↓, *ROS↓, *OCR↓,
3140- VitC,    Vitamin-C-dependent downregulation of the citrate metabolism pathway potentiates pancreatic ductal adenocarcinoma growth arrest
- in-vitro, PC, MIA PaCa-2 - in-vitro, Nor, HEK293
citrate↓, FASN↓, ACLY↓, LDH↓, Glycolysis↓, Warburg↓, PDK1↓, GLUT1↓, LDHA↓, ECAR↓, PDH↑, eff↑,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis

ACLY↓, 3,   AMPK↑, 1,   citrate↓, 1,   CRM↑, 1,   ECAR↓, 1,   FASN↓, 1,   Glycolysis↓, 1,   LDH↓, 1,   LDHA↓, 1,   LDL↓, 1,   lipoGen↓, 1,   PDH↑, 1,   PDK1↓, 1,   Warburg↓, 1,  

Autophagy & Lysosomes

TumAuto↑, 1,  

Proliferation, Differentiation & Cell State

TumCG↓, 1,  

Barriers & Transport

GLUT1↓, 1,  

Immune & Inflammatory Signaling

Inflam↓, 1,  

Drug Metabolism & Resistance

Dose↝, 1,   eff↑, 1,  

Clinical Biomarkers

LDH↓, 1,  

Functional Outcomes

cardioP↑, 1,   toxicity∅, 1,  
Total Targets: 23

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

ROS↓, 1,  

Mitochondria & Bioenergetics

OCR↓, 1,  

Core Metabolism/Glycolysis

ACLY↓, 1,   LDL↓, 1,  

Functional Outcomes

MusCon↓, 1,  
Total Targets: 5

Scientific Paper Hit Count for: ACLY, ATP citrate lyase
2 bempedoic acid
1 HydroxyCitric Acid
1 Vitamin C (Ascorbic Acid)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:49  Cells:%  prod#:%  Target#:2  State#:%  Dir#:1
wNotes=0 sortOrder:rid,rpid

 

Home Page